Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Agrippal S1 (2010-2011 Formulation) in Adults and Elderly
NCT01151059Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2010
- Primary completion
- Jun 2010
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Agrippal S1 in influenza, sponsored by Novartis. Primary endpoint: Antibody response to each influenza vaccine antigen at 21 days. Started Jun 2010; status: completed.
02
Drugs
Agrippal S1
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01151059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01151059.